Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K.

Crit Rev Oncol Hematol. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.

PMID:
30771872
2.

Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

Hamy AS, Tury S, Wang X, Gao J, Pierga JY, Giacchetti S, Brain E, Pistilli B, Marty M, Espié M, Benchimol G, Laas E, Laé M, Asselain B, Aouchiche B, Edelman M, Reyal F.

J Clin Oncol. 2019 Jan 31:JCO1800636. doi: 10.1200/JCO.18.00636. [Epub ahead of print]

PMID:
30702971
3.

Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach.

Laas E, Hamy AS, Michel AS, Panchbhaya N, Faron M, Lam T, Carrez S, Pierga JY, Rouzier R, Lerebours F, Feron JG, Reyal F.

PLoS One. 2019 Jan 23;14(1):e0208807. doi: 10.1371/journal.pone.0208807. eCollection 2019.

4.

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial.

Bernard-Tessier A, Jeannot E, Guenat D, Debernardi A, Michel M, Proudhon C, Vincent-Salomon A, Bièche I, Pierga JY, Buecher B, Meurisse A, François É, Cohen R, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Borg C, Bidard FC, Kim S.

Clin Cancer Res. 2018 Nov 30. doi: 10.1158/1078-0432.CCR-18-2984. [Epub ahead of print]

PMID:
30504426
5.

Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.

Cabel L, Carton M, Cheaib B, Pierga JY, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Desmoulins I, Lefeuvre C, Gonçalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Perrocheau G, Piot I, Pérol D, Simon G, Lerebours F.

Breast Cancer Res Treat. 2018 Oct 24. doi: 10.1007/s10549-018-5017-2. [Epub ahead of print]

PMID:
30357526
6.

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions.

Decraene C, Bortolini Silveira A, Michel M, Bidard FC, Pierga JY, Stern MH, Proudhon C.

J Vis Exp. 2018 Sep 25;(139). doi: 10.3791/58051.

PMID:
30320738
7.

Disseminated Tumor Cells Predict Efficacy of Regional Nodal Irradiation in Early Stage Breast Cancer.

Mignot F, Loirat D, Dureau S, Bataillon G, Caly M, Vincent-Salomon A, Berger F, Fourquet A, Pierga JY, Kirova YM, Bidard FC.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):389-396. doi: 10.1016/j.ijrobp.2018.09.033. Epub 2018 Oct 4.

PMID:
30291993
8.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.

Cabel L, Jeannot E, Bieche I, Vacher S, Callens C, Bazire L, Morel A, Bernard-Tessier A, Chemlali W, Schnitzler A, Lièvre A, Otz J, Minsat M, Vincent-Salomon A, Pierga JY, Buecher B, Mariani P, Proudhon C, Bidard FC, Cacheux W.

Clin Cancer Res. 2018 Nov 15;24(22):5767-5771. doi: 10.1158/1078-0432.CCR-18-0922. Epub 2018 Jul 27.

PMID:
30054279
9.

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.

Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern MH, Pierga JY, Bidard FC.

Nat Rev Clin Oncol. 2018 Oct;15(10):639-650. doi: 10.1038/s41571-018-0074-3. Review.

PMID:
30050094
10.

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer.

Tanguy ML, Cabel L, Berger F, Pierga JY, Savignoni A, Bidard FC.

NPJ Breast Cancer. 2018 Jun 26;4:14. doi: 10.1038/s41523-018-0068-4. eCollection 2018. Review.

11.

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

Jacquinot Q, Paget-Bailly S, Fumoleau P, Romieu G, Pierga JY, Espié M, Lortholary A, Nabholtz JM, Mercier CF, Pauporté I, Henriques J, Pivot X.

Breast. 2018 Oct;41:1-7. doi: 10.1016/j.breast.2018.06.001. Epub 2018 Jun 15.

PMID:
29913374
12.

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.

Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching PA, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart M, Sotiriou C, Rack B, Pierga JY.

Ann Oncol. 2018 Aug 1;29(8):1777-1783. doi: 10.1093/annonc/mdy211.

PMID:
29893791
13.

Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.

Bacrie J, Laurans M, Iorio P, Fourme E, Volters AB, Bozec L, Lerebours F, Dubot C, Bensaoula O, Benzidane B, Pierga JY, Lefeuvre D.

Support Care Cancer. 2018 Dec;26(12):4097-4103. doi: 10.1007/s00520-018-4280-4. Epub 2018 May 31.

PMID:
29855772
14.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
15.

Circulating tumor DNA detection in hepatocellular carcinoma.

Cabel L, Proudhon C, Buecher B, Pierga JY, Bidard FC.

Ann Oncol. 2018 May 1;29(5):1094-1096. doi: 10.1093/annonc/mdy111. No abstract available.

PMID:
29635453
16.

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.

DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I.

Anticancer Res. 2018 Mar;38(3):1485-1490.

PMID:
29491076
17.

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.

Hamy AS, Belin L, Bonsang-Kitzis H, Paquet C, Pierga JY, Lerebours F, Cottu P, Rouzier R, Savignoni A, Lae M, Reyal F.

Br J Cancer. 2018 Mar 20;118(6):e14. doi: 10.1038/bjc.2018.4. Epub 2018 Feb 20.

18.

Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.

Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Coussy F, Becette V, Bonsang-Kitzis H, Rouzier R, Feron JG, Benchimol G, Laé M, Reyal F.

Breast Cancer Res Treat. 2018 Jun;169(2):295-304. doi: 10.1007/s10549-017-4610-0. Epub 2018 Jan 27.

PMID:
29374852
19.

Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR.

Decraene C, Silveira AB, Bidard FC, Vallée A, Michel M, Melaabi S, Vincent-Salomon A, Saliou A, Houy A, Milder M, Lantz O, Ychou M, Denis MG, Pierga JY, Stern MH, Proudhon C.

Clin Chem. 2018 Feb;64(2):317-328. doi: 10.1373/clinchem.2017.272518. Epub 2017 Nov 9.

20.

Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study.

Laroche F, Perrot S, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Chauvenet L, Bouhassira D, Coste J.

PLoS One. 2017 Nov 8;12(11):e0187165. doi: 10.1371/journal.pone.0187165. eCollection 2017.

21.

A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.

Criscitiello C, Bayar MA, Curigliano G, Symmans FW, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, André F.

Ann Oncol. 2018 Jan 1;29(1):162-169. doi: 10.1093/annonc/mdx691.

PMID:
29077781
22.

Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.

Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, Vincent-Salomon A, Cottu P, Lerebours F, Rouzier R, Lae M, Reyal F.

Ann Oncol. 2017 Sep 1;28(9):2233-2240. doi: 10.1093/annonc/mdx309.

PMID:
28911063
23.

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.

Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Thomas G, Deleuze JF, Pauporté I, Romieu G, Cox DG.

Breast Cancer Res. 2017 Aug 22;19(1):98. doi: 10.1186/s13058-017-0888-4.

24.

Circulating tumor cell count and thrombosis in metastatic breast cancer.

Beinse G, Berger F, Cottu P, Dujaric ME, Kriegel I, Guilhaume MN, Diéras V, Cabel L, Pierga JY, Bidard FC.

J Thromb Haemost. 2017 Oct;15(10):1981-1988. doi: 10.1111/jth.13792. Epub 2017 Sep 1.

PMID:
28779538
25.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC.

Eur J Cancer. 2017 Sep;83:185-193. doi: 10.1016/j.ejca.2017.05.016. Epub 2017 Jul 22.

PMID:
28743036
26.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.

Pivot X, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Agostini C, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Calvo F, Renaud A, Deleuze JF, Pauporté I, Thomas G, Cox DG.

NPJ Breast Cancer. 2017 Feb 23;3:4. doi: 10.1038/s41523-017-0005-y. eCollection 2017.

27.

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

Pivot X, Fumoleau P, Pierga JY, Delaloge S, Bonnefoi H, Bachelot T, Jouannaud C, Bourgeois H, Rios M, Soulié P, Jacquin JP, Lavau-Denes S, Kerbrat P, Cox D, Faure-Mercier C, Pauporte I, Gligorov J, Curtit E, Henriques J, Paget-Bailly S, Romieu G.

Eur J Cancer. 2017 Aug;81:151-160. doi: 10.1016/j.ejca.2017.05.020. Epub 2017 Jun 16.

PMID:
28624696
28.

San Antonio 2016: Progress on the Long Way to Individualized Treatment of Breast Cancer.

Müller V, Gluz O, Pierga JY, Thill M, Rack B, Witzel I.

Breast Care (Basel). 2017 Mar;12(1):54-58. doi: 10.1159/000458749. Epub 2017 Feb 28. No abstract available.

29.

[Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center].

Ngo C, Laé M, Ratour J, Hamel F, Taris C, Caly M, Le Cunff A, Reyal F, Kirova Y, Pierga JY, Vincent-Salomon A.

Bull Cancer. 2017 Jul - Aug;104(7-8):608-617. doi: 10.1016/j.bulcan.2017.05.002. Epub 2017 Jun 7. French.

PMID:
28595742
30.

Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.

Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher B, Piperno-Neumann S, Bernard V, Baulande S, Bieche I, Pierga JY, Proudhon C, Bidard FC.

Ann Oncol. 2017 Aug 1;28(8):1996-2001. doi: 10.1093/annonc/mdx212.

PMID:
28459943
31.

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.

Ng CKY, Bidard FC, Piscuoglio S, Geyer FC, Lim RS, de Bruijn I, Shen R, Pareja F, Berman SH, Wang L, Pierga JY, Vincent-Salomon A, Viale A, Norton L, Sigal B, Weigelt B, Cottu P, Reis-Filho JS.

Clin Cancer Res. 2017 Aug 1;23(15):4402-4415. doi: 10.1158/1078-0432.CCR-16-3115. Epub 2017 Mar 28.

32.

Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.

Ajgal Z, de Percin S, Diéras V, Pierga JY, Campana F, Fourquet A, Kirova YM.

Cancer Radiother. 2017 Apr;21(2):114-118. doi: 10.1016/j.canrad.2016.10.002. Epub 2017 Mar 24.

PMID:
28347625
33.

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Ann Oncol. 2017 Dec 1;28(12):3111. doi: 10.1093/annonc/mdx036. No abstract available.

34.

First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.

Dieras V, Pop S, Berger F, Dujaric ME, Beuzeboc P, Escalup L, Bidard FC, Cottu PH, LE Tourneau C, Piperno-Neumann S, Laurence V, Robain M, Asselain B, Pierga JY.

Anticancer Res. 2017 Mar;37(3):1403-1407.

PMID:
28314310
35.

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

Giacchetti S, Hamy AS, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Saghatchian M, Lerebours F, Mazouni C, Tembo O, Espié M, Reyal F, Marty M, Asselain B, Pierga JY.

Eur J Cancer. 2017 Apr;75:323-332. doi: 10.1016/j.ejca.2017.01.008. Epub 2017 Mar 7.

PMID:
28279941
36.

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.

Bonsang-Kitzis H, Mouttet-Boizat D, Guillot E, Feron JG, Fourchotte V, Alran S, Pierga JY, Cottu P, Lerebours F, Stevens D, Vincent-Salomon A, Sigal-Zafrani B, Campana F, Rouzier R, Reyal F.

PLoS One. 2017 Feb 27;12(2):e0169962. doi: 10.1371/journal.pone.0169962. eCollection 2017.

37.

Circulating tumor cells: clinical validity and utility.

Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY, Bidard FC.

Int J Clin Oncol. 2017 Jun;22(3):421-430. doi: 10.1007/s10147-017-1105-2. Epub 2017 Feb 25. Review.

PMID:
28238187
38.

Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?

Cabel L, Proudhon C, Mariani P, Tzanis D, Beinse G, Bieche I, Pierga JY, Bidard FC.

Eur J Surg Oncol. 2017 May;43(5):949-962. doi: 10.1016/j.ejso.2017.01.010. Epub 2017 Jan 29. Review.

PMID:
28185687
39.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.

Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, Lerebours F, Bachelot T, Kerbrat P, Campone M, Eymard JC, Mouret-Reynier MA, Gligorov J, Hardy-Bessard AC, Lortholary A, Soulie P, Boher JM, Proudhon C, Charafe-Jaufret E, Lemonnier J, Bertucci F, Viens P.

Ann Oncol. 2017 Jan 1;28(1):103-109. doi: 10.1093/annonc/mdw535.

PMID:
28177480
40.

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544. No abstract available. Erratum in: Ann Oncol. 2017 Dec 1;28(12 ):3111.

41.

Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259].

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Breast. 2017 Apr;32:269-270. doi: 10.1016/j.breast.2017.01.001. Epub 2017 Jan 18. No abstract available.

PMID:
28109648
42.

Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Riva F, Bidard FC, Houy A, Saliou A, Madic J, Rampanou A, Hego C, Milder M, Cottu P, Sablin MP, Vincent-Salomon A, Lantz O, Stern MH, Proudhon C, Pierga JY.

Clin Chem. 2017 Mar;63(3):691-699. doi: 10.1373/clinchem.2016.262337. Epub 2017 Jan 10.

43.

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.

Rochefort P, Chabaud S, Pierga JY, Tredan O, Brain E, Bidard FC, Schiffler C, Polena H, Khalil-Mgharbel A, Vilgrain I, Bachelot T.

Br J Cancer. 2017 Jan;116(3):356-361. doi: 10.1038/bjc.2016.427. Epub 2017 Jan 5.

44.

FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells.

Perez-Toralla K, Mottet G, Tulukcuoglu-Guneri E, Champ J, Bidard FC, Pierga JY, Klijanienko J, Draskovic I, Malaquin L, Viovy JL, Descroix S.

Methods Mol Biol. 2017;1547:211-220. doi: 10.1007/978-1-4939-6734-6_16.

PMID:
28044298
45.

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Breast. 2017 Feb;31:244-259. doi: 10.1016/j.breast.2016.10.001. Epub 2016 Dec 5. No abstract available. Erratum in: Breast. 2017 Apr;32:269-270.

46.

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.

Cox DG, Curtit E, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Deleuze JF, Pauporté I, Thomas G, Pivot X.

Oncotarget. 2016 Nov 22;7(47):77358-77364. doi: 10.18632/oncotarget.12669.

47.

Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years.

Lebon V, Alberini JL, Pierga JY, Diéras V, Jehanno N, Wartski M.

J Nucl Med. 2017 Feb;58(2):252-257. doi: 10.2967/jnumed.116.178749. Epub 2016 Sep 1.

48.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.

N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.

49.

Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery.

Gosset M, Hamy AS, Mallon P, Delomenie M, Mouttet D, Pierga JY, Lae M, Fourquet A, Rouzier R, Reyal F, Feron JG.

PLoS One. 2016 Aug 5;11(8):e0159888. doi: 10.1371/journal.pone.0159888. eCollection 2016.

50.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G.

Nat Commun. 2016 Jul 13;7:12222. doi: 10.1038/ncomms12222.

Supplemental Content

Loading ...
Support Center